SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending after news of a significant investment and partnership with Nvidia, boosting confidence in the company's AI and chip manufacturing prospects; the community is discussing the potential long-term impacts and whether this marks a true turnaround for the stock, with some speculating on future partnerships and price targets while considering possible pullbacks after the initial surge.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is currently a hot topic, with community members expressing excitement and anticipation for potential price increases. Conversations revolve around breaking resistance levels and the potential for Pyth to integrate further with the Solana ecosystem. Some users are comparing it to other trending coins, while others discuss its potential applications in bringing economic data on-chain.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending amid a sharp decline, with community members debating whether it's an oversold opportunity or a value trap. Discussions revolve around potential market manipulation, competition from walled gardens like Amazon and Netflix, and the CEO's silence. Some investors express frustration while others see it as a buying opportunity, citing strong fundamentals and potential for a rebound.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards AI and high-performance computing, sparked by recent CEO commentary. The community is analyzing key resistance levels, with many believing the stock is undervalued compared to its peers and poised for a significant rally. Bullish sentiment surrounds the stock as traders anticipate further developments in its strategic shift.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

Brera Holdings PLC (BREA) is trending after announcing a $300M private placement to launch a Solana-backed digital asset treasury, rebranding as Solmate. Community members are discussing the potential for significant gains, drawing comparisons to similar crypto treasury plays, and noting ARK Invest's involvement. Some traders caution against chasing the stock, citing potential dilution.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending amid increasing community optimism, potentially driven by news surrounding the upcoming NIO Day and positive remarks from analysts. Investors are actively discussing the stock's potential to reach new 52-week highs and the possibility of a parabolic move. Bullish sentiment seems to be fueled by expectations surrounding new model launches and growing confidence in the company's future profitability.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer is trending as the community awaits the full release of Caffeine AI, with many believing it will drive adoption and utility for the token. While some express excitement about potential gains and the tech's capabilities, others remain skeptical, citing concerns about marketing and competition from centralized AI solutions. Discussions also include staking rewards and comparisons to other blockchains, reflecting a mix of optimism and caution.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI ($SOUN) is trending as investors discuss its potential for a short squeeze, fueled by high short interest and anticipation of positive catalysts. Community members are pointing to technical indicators suggesting a breakout, while also speculating on potential partnerships and the company's growth prospects in the AI-driven customer service sector. The stock is experiencing high options volume, with traders eyeing potential price targets amid bullish sentiment.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as investors react to news of a new Air Force contract and broader enthusiasm for the quantum computing sector, drawing comparisons to past high-growth stocks. Community members are debating the stock's valuation and potential, with some highlighting institutional ownership and others cautioning against overvaluation. Option activity is elevated, suggesting increased speculative interest in RGTI's near-term price movement.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions about its upcoming e-bike launch, production plans, and partnerships, including the new Georgia plant and the VW Group collaboration. Community members are actively debating the potential impacts of these developments on Rivian's future profitability and market position. Sentiment is mixed, with some expressing optimism and others voicing concerns about cash burn and competition within the EV sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35.&nbsp;The firm said recent stumbles in Schrodinger’s homegrown drug programs, along with persistent headwinds across biotech and pharma, have dimmed its outlook.<a href="https://stocktwits.com/symbol/SDGR">Shares of Schrodinger</a> fell 2% to $19.45 on Thursday, marking its lowest close in four months, before edging up 0.2% to $19.5 in after-hours trading.The downgrade by the brokerage firm came just after Schrodinger disclosed that it will&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/schrodinger-discontinues-clinical-program-after-two-patient-deaths/chsR0RyRdOb">discontinue the development of SGR-2921</a>, an early-stage CDC7 inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.Chief Medical Officer Margaret Dugan said patient safety was the company’s top priority, noting that the drug’s potential as a combination therapy would be challenging to pursue under the circumstances. “While disappointing given the early clinical activity observed, we believe this is the right decision for patients,” she said.Citi said its earlier bullish stance had hinged on three early-stage Phase 1 assets that could validate Schrodinger’s drug discovery platform and attract biopharma partners.&nbsp;The brokerage firm noted that updates so far have “fallen short,” fueling concerns about the future of the company’s internal drug portfolio.SGR-2921 was&nbsp;designed to block CDC7 kinase, a protein overexpressed in many cancers and involved in DNA replication and cell cycle progression.&nbsp;Preclinical data had suggested the drug could work in combination with standard-of-care agents, but Schrodinger said the safety risks outweighed the potential benefits.On Stocktwits, retail sentiment for Schrodinger was ‘bearish’ amid ‘extremely high’ message volume.One user questioned the timing of Schrodinger’s disclosure, noting that the company reported Q2 earnings just eight days ago, and&nbsp;wondered if both patient deaths occurred since then or if the information had been withheld.&nbsp;<stembedurl>https://stocktwits.com/scott52/message/625133866</stembedurl>Another user speculated that there was “more to the news” than disclosed, pointing to the stock’s quick price recovery as a sign that “something fishy” might be going on.<stembedurl>https://stocktwits.com/Buckanator/message/625153259</stembedurl>Schrodinger’s stock has risen 0.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Schrodinger logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern

Shares closed at a four-month low before edging slightly higher after hours as investors digested the pipeline setback and cautious outlook.

Equity

Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.The decision was made in light of two treatment-related deaths in the early-stage study, the company said. <a href="https://stocktwits.com/symbol/SDGR">Schrödinger</a> opined that developing the drug as a combination therapy would be difficult to pursue in light of the two deaths despite evidence of activity as a monotherapy.Margaret Dugan, chief medical officer at Schrödinger, <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.schrodinger.com/press-releases/news-details/2025/Schrdinger-Announces-Discontinuation-of-SGR-2921-Program/default.aspx">said</a>, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”On Stocktwits, retail sentiment around SDGR fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. The stock is trading 4% lower in the pre-market session on Thursday.Dugan said the company had hoped to advance the investigational drug for acute myeloid leukemia, a rapidly progressing cancer of the blood and bone marrow, provided there are limited therapies available for the disease. The early-stage study was also supported by preclinical data, which suggested that SGR-2921 could ultimately be used in combination with standard-of-care agents, the company said.SGR-2921 is a CDC7 inhibitor, meaning it is a drug that blocks the activity of the CDC7 kinase, a protein involved in DNA replication and cell cycle progression. CDC7 is often overexpressed in cancer cells, and its inhibition can lead to cell cycle arrest and programmed cell death of these cancer cells.SDGR stock is up by 3% this year and by over 4% in the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-as-investors-await-wholesale-inflation-data/chsRirXRdOG">Dow Futures Edge Lower As Wall Street Watches Out For PPI Report: BLSH, COHR, CSCO Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Schrödinger Discontinues Clinical Program After Two Patient Deaths

SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of +28.92% and +5.08%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and -1.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?

VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Schrodinger (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.74	--	--	N/A
Q2 '25	-$0.77	-$0.59	23.16%	BEAT
Q1 '25	-$0.73	-$0.82	-12.96%	MISSED
Q4 '24	-$0.42	-$0.55	-29.64%	MISSED
Q3 '24	-$0.63	-$0.52	17.83%	BEAT

SDGR
Schrodinger Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SDGR News

SDGR Schrodinger Inc